Brain Tumour Research Centre of Excellence, University of Plymouth Research Symposium
 
  • Lecture Theatre, John Bull Building, Plymouth Science Park, 16 Research Way, Plymouth PL6 8BU

Save event
The Brain Tumour Research Centre of Excellence at the University of Plymouth is one of three UK Centres of Excellence funded by the charity Brain Tumour Research. This symposium is to celebrate some of our achievements and stimulate discussion with clinicians on the ground. 
We will cover topics such as the mechanism of tumour development, genetics and new treatment avenues.
PROGRAMME
13:30–14:10 | Registration, light lunch and refreshments
14:10–14:20 | Keynote opening by Professor Oliver Hanemann, Peninsula Medical School, University of Plymouth 
14:20–15:10 | Keynote: 'Pituitary genetics for neurosurgeons’ by Professor Márta Korbonits, Barts Health NHS Trust  
15:10–15:30 | ‘Brain tumour initiation and growth control by mitochondrial YME1L' by Dr Jon Gil Ranedo, Peninsula Medical School, University of Plymouth 
15:30–15:50 | ‘Targeting the Hippo Pathway in NF2-null meningioma and schwannoma tumours' by Dr Liyam Laraba, Peninsula Medical School, University of Plymouth 
15:50–16:40 | Break for refreshments and poster session   
 16:40–17:30 | Keynote: 'Can we cure glioma with cannabinoids?' by Professor Susan Short, School of Medicine, University of Leeds 
 17:30–17:50 | ‘Improving radiotherapeutic efficacy with HDAC inhibitor in meningioma' by Dr Juri Na, Peninsula Medical School, University of Plymouth 
 17:50–18:10 | ‘Establishment of a novel 3D meningioma cell culture model and its validation for use as tool in drug development ' by Ms Laurien van de Weijer, Peninsula Medical School, University of Plymouth 
 18:10–18:15 | Event close 

Register attendance

Previous January 2023 Next
Mon Tue Wed Thu Fri Sat Sun
26
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
 

Keynote speakers

Márta is a graduate from the Semmelweis Medical School, Budapest. 
She was a Medical Research Council Clinician Scientist Fellow working on ghrelin and the hormonal regulation of the metabolic enzyme AMP-activated protein kinase and her latest study in the field showed the beneficial effects of AMPK stimulator metformin on glucocorticoid treated patients. Márta also works on endocrine tumorigenesis, especially the genetic origin of pituitary adenomas and other endocrine tumour syndromes. She studies both the clinical characterisation as well as molecular aspects of pituitary diseases and leads a large international consortium to study the genetic background of endocrine tumours. She published over 200 original papers (H-index 81 at Google Scholar). Márta shares her time between clinical patient care, clinical research and laboratory-based research as well as teaching at undergraduate and postgraduate level. 
She was a recipient of several national and international awards, including the 2022 Rolf Gaillard prize, and is an elected Member of the Hungarian Academy of Sciences. She is Deputy Editor of Endocrine-Related Cancer and Director of the HARP Clinical Doctoral Training Programme. She is President-Elect for the Society for Endocrinology. 
<p>
















Márta Korbonits, MD, PhD, DSc, FRCP is Professor of Endocrinology and
Metabolism at Barts and the London School of Medicine and Dentistry, Queen Mary
University of London



<br></p>

Professor Márta Korbonits

Márta Korbonits, MD PhD DSc FRCP, is Professor of Endocrinology and Metabolism at Barts and the London School of Medicine and Dentistry, Queen Mary University of London. 
Susan is an academic oncologist with a research interest in the treatment of adult brain tumours. This includes clinical research in technical radiotherapy developments as well as drug-radiotherapy combinations in early phase clinical studies. 
She is PI for a portfolio of local and national clinical studies. Her recent laboratory work has included investigation of oncolytic viruses as immune stimulants and adjuvants in gliomas, targeting micro-RNA biology in gliomas and identifying novel approaches to preventing DNA repair following cytotoxic treatments. 
Susan has many years of experience in developing and leading major national clinical research groups including Chairing the NCRI Brain Tumour Clinical Study Group, The NCRI CTRad pre-clinical workstream and the Clinical Committee of the British Neuro Oncology Society. 
She has been involved in collaborative network activity in EU FP7 (INSERT) as well as national radiotherapy research (ART-NET and RAD-NET) and national glioma consortia (BRAIN-MATRIX). 
She currently leads an international consortium addressing liquid biomarkers in glioma (BRAIN-LBC) and is president of the European Association of Neuro Oncology.
<p>

Susan Short MBBS BSc MRCP FRCR PhD is Professor in the School of Medicine at the University of Leeds and consultant Clinical Oncologist at St James’s University Hospital, Leeds.

<br></p>

Professor Susan Short

Susan Short, MBBS BSc MRCP FRCR PhD, is Professor in the School of Medicine at the University of Leeds and consultant Clinical Oncologist at St James’s University Hospital, Leeds.
 

The University of Plymouth is a Brain Tumour Research Centre of Excellence, currently one of only three in the UK. 
The world-leading research in Professor Hanemann’s laboratories seeks to discover new treatments and a cure for low-grade brain tumours, for the benefit of patients and their families.
Find out more about our world-leading brain tumour research

<p>

Caprice and Brain Tumour Research supporters at the Plymouth Centre of Excellence 

<br></p>

Caprice, Brain Tumour Research researchers and Brain Tumour Research supporters at the Plymouth Centre of Excellence

 

Brain Tumour Research is an official charity partner of the University of Plymouth. We're one of only three universities in the UK currently working with the charity to improve the treatment and outcomes of brain tumours.

  • Brain tumours continue to kill more children and adults under 40 than any other cancer.
  • There are over 120 different types of brain tumour.
  • It is estimated that around 16,000 people a year in the UK are diagnosed with a brain tumour.
  • Less than 20% of brain tumour patients survive beyond five years of their diagnosis.
  • Ten people a day die of a brain tumour.
Statistics provided by Brain Tumour Research.

 

Our Centre of Excellence is one of Europe’s leading research institutes for low-grade brain tumours.
The Plymouth team, led by Professor Oliver Hanemann, has a world-leading track record in researching low-grade brain tumours occurring in teenagers and adults. By identifying and understanding the mechanism that makes a cell become cancerous, the team are exploring ways to halt or reverse them.
Click your way through the lab and watch videos of researchers explaining how they are working to gain a deeper understanding of the disease, developing new treatments and therapies and ultimately getting closer to finding a cure. Discover the equipment that scientists use every day to make ground-breaking steps in brain tumour research, and visit the Wall of Hope to see tiles which have been placed by our amazing supporters who have sponsored a day of research.

<p>Image for publications&nbsp;on BTR lab page</p>
 

Coronavirus (COVID-19)

We are constantly monitoring the COVID-19 pandemic and its impact. The University remains open with a safety-first approach to ensure our campuses are ‘covid-secure’ for our staff, students, local community and visitors, in accordance with government guidance.

University advice and guidance on COVID-19


Event photography and video

Please be aware that some of the University of Plymouth's public events (both online and offline) may be attended by University staff, photographers and videographers, for capturing content to be used in University online and offline marketing and promotional materials, for example webpages, brochures or leaflets. If you, or a member of your group, do not wish to be photographed or recorded, please let a member of staff know.